Market Research Logo

The World Market for Orphan Drugs (Markets for Oncology, Hematology, Neurology, Endocrine, Metabolic and Other Drugs)

In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S., Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments.

Osteoporosis, arthritis, Alzheimer’s, and Parkinson’s are major factors affecting quality of life. Mortality from cancer, diabetes, liver and kidney diseases has been slow to change, offering significant areas for research breakthroughs. Cancer, poorly served by traditional chemotherapies, is a major opportunity for biotech firms because the investment compared to return can be favorable: the field has high priority with regulatory authorities who are willing to give it fast track status on the basis of smaller (and therefore cheaper) clinical trials (a few extra months of survival could be enough to win FDA approval); the clinical community is highly concentrated; and the market size is often larger than the approved indication because of a high off-label use (for other cancers). Infectious diseases, the third most common cause of death in many geographic regions, highlight the pressing need for new therapies with novel mechanisms of action to avoid growing issues affecting this industry including a top area of concern—drug resistance.

This report provides estimates for the world market for orphan drugs, as well as the E.U. and Japan markets. Given the size of the U.S. opportunity, the report offers in-depth market data for the U.S. market. Several segments are discussed, including:

  • Oncology
  • Hematology
  • Musculoskeletal
  • Neurology
  • Endocrine
  • Metabolic
  • Others
These segments are the most common areas of development and success for orphan drug developers/marketers which required providing detailed information about these orphan drug market segments.

In the U.S., a drug may be designated an orphan drug if the disease or condition for which it is indicated, affects less than 200,000 Americans. Orphan medicinal products in the E.U. member states are intended for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons. In Japan an orphan drug may be designated for a patient population of less than 50,000 and provide for an unmet medical need. Other countries have similar designations. These three regional markets for drugs are examined in separate sections of the report.

Analysis of The “Pure” Orphan Drug Market

Some publicized estimates of orphan drug markets include brand revenue that is not truly related to the orphan status of the drug. In this unique research effort, Kalorama Information separates strictly orphan revenue from total brand revenue where necessary to provide a true picture of the pure orphan drug market opportunity. The world orphan drug market is difficult to determine due to the variances in orphan drug status and requirements by country. Products may be available as an orphan drug on one country and be a traditional marketing approval for another country. In addition, some products gain orphan status, are granted approval and then removed from the orphan drug database at the request of the developer. There are a number of factors involved, including reimbursement by country, regulation by country, disease status by country and general development by country.

For this market research report, market numbers discussed in this report are focused on the global market in brief with in-depth market coverage of the U.S. market. Additionally, there is select coverage for the European Union and Japanese market. All sales are displayed at the manufacturers’ level in U.S. dollars.

This report includes orphan drugs. In cases where sales are generated by indications for both orphan indications and non-orphan indications, we have attempted to extract just the orphan portion of sales. The base year is 2012, with forecasts provided for each year through 2017. The market was generated using estimates of individual product sales and compared with market data from a combination of other methods including disease prevalence trends, population trends, pricing trends, government regulations and reimbursements. Both primary and secondary sources were consulted in developing market estimates.

Demographics, Costs, Regulation and Other Trends Examined

The list of trends and factors affecting the orphan drug market remain lengthy. The orphan drug market is affected by both trends that affect the pharmaceutical industry as a whole and trends that specifically affect the orphan drug market:
  • Orphan drug pricing
  • Aging of the population
  • Increasing life expectancy
  • Trends in birth rates
  • Cost effectiveness
  • Regulatory environments
  • Orphan drug incentives
  • Population demographics
  • Product availability by country/region
Due to the wide variety of products to receive orphan designations, there are numerous developers with products in this area. Some of the developers that have received an orphan designation have followed through to receive a full product approval but others may not gain additional approvals.

Extensive Company Coverage

The report looks extensively at what major pharmaceutical companies and smaller concerns are doing within this drug category. The report provides company market share for both the US and global markets. A variety of companies with both designations and designation/approvals are discussed in this report:
  • Abbott Laboratories
  • AbbVie
  • Actelion
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter
  • Bayer
  • Bio Products Laboratory
  • Biogen IDEC
  • BioMarin Pharmaceuticals
  • Boehringer-Ingelheim
  • Bristol-Myers Squibb
  • Cangene
  • Celgene
  • CSL Behring
  • Depomed
  • Eisai
  • Eli Lilly & Co.
  • EMD Serono
  • Exelixis
  • Gilead Sciences
  • GlaxoSmithKline
  • ImmunoGen
  • Insmed
  • Johnson & Johnson
  • Luitpold Pharmaceuticals
  • Merck & Co
  • Millennium Pharmaceuticals
  • NBI Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • NPS Pharmaceuticals
  • Pfizer
  • Roche
  • Sanofi
  • Seattle Genetics
  • Shire
  • Sigma-Tau
  • Soligenix
  • Spectrum Pharmaceuticals
  • Swedish Orphan Biovitrum
  • TEVA
  • United Therapeutics
  • Valeant Pharmaceuticals
  • XenoPort
Biological therapies have increasingly become the treatment of choice for many diseases. Several hundred million individuals worldwide have been helped by more than 150 therapies. Many of these areas of treatment have huge numbers of individuals affected each year while other areas are small but growing due to the advancement in treatment, superior therapies, and development incentives--such as those that accompany orphan drug designation/approvals.

Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with more than 130 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with leading orphan drug developers' representatives including marketing directors, division managers, and product representatives, were consulted. Secondary sources such as company literature, databases, investment reports, and business journals were used to complement primary information.


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
      • Market Segments
    • ISSUES AND TRENDS
    • WORLD MARKET SUMMARY
      • Table World Orphan Drug Market 2007-2017 (in millions of dollars)
    • COMPETITORS
  • Introduction
    • OVERVIEW
    • HISTORY OF THE U.S. ORPHAN DRUG MARKET
    • PHARMACEUTICAL RESEARCH&DEVELOPMENT OVERVIEW
      • Table Phases of Clinical Drug Development
    • PHARMACEUTICAL INDUSTRY IMPORTANT REGULATORY TERMS
    • DISEASES AND ORPHAN DRUG IMPACT
    • DISEASE DESCRIPTIONS
      • Blood Disorders
      • Cancer
        • Table Total Cancer Incidence by Sex and Country
      • Hormone Disorders
      • Infectious Diseases
    • THE COST SIDE OF ORPHAN DRUGS
      • Table Average Annual Drug Costs to Patients, Selected Drugs
  • U.S. Orphan Drugs
    • OVERVIEW
      • Table Orphan Drug Designations Granted and Approvals by the FDA 1983-2013*
    • RECENT ORPHAN DRUG DESIGNATIONS
      • Table 12-Months Orphan Drug Designations Granted by FDA (May 1, 2012 - May 1, 2013)
    • ORPHAN DRUG APPROVALS BY COMPANY
      • Abbott Laboratories
        • Table Abbott Laboratories' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Acorda Therapeutics
        • Table Acorda Therapeutics' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Actelion Pharmaceuticals
        • Table Actelion Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Aegerion Pharmaceuticals
        • Table Aegerion Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Alexion Pharmaceuticals
        • Table Alexion Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Allergan, Inc.
        • Table Allergan's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Amgen
        • Table Amgen's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Ariad Pharmaceuticals
        • Table Ariad Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Astellas
        • Table Astellas' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • AstraZeneca
        • Table AstraZeneca's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table MedImmune's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Auxilium Pharmaceuticals, Inc.
        • Table Auxilium Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Bausch & Lomb
        • Table Bausch & Lomb's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Baxter International
        • Table Baxter International's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Bayer AG
        • Table Bayer's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Biogen IDEC
        • Table Biogen IDEC's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • BioMarin Pharmaceutical, Inc.
        • Table BioMarin Pharmaceutical's Orphan Drug Approvals Granted by FDA (1989 - May 1, 2013)
      • Boehringer Ingelheim
        • Table Boehringer Ingelheim's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Bristol-Myers Squibb
        • Table Bristol-Myers's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Cangene Corporation
        • Table Cangene's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Celgene Corporation
        • Table Celgene Corporation's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • CSL Behring
        • Table CSL Behring's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Eisai Co., Ltd.
        • Table Eisai's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Eli Lilly & Company
        • Table Eli Lilly's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • EMD Serono
        • Table EMD Serono's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Endo Health Solutions, Inc.
        • Table Endo Health Solutions' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Exelixis, Inc.
        • Table Exelixis' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Gilead Sciences, Inc.
        • Table Gilead Sciences' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • GlaxoSmithKline
        • Table GlaxoSmithKline's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Grifols, S.A.
        • Table Grifols' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Hyperion Therapeutics, Inc.
        • Table Hyperion Therapeutics' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Incyte Corporation
        • Table Incyte Corporation's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Ipsen, Inc.
        • Table Ipsen's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Jazz Pharmaceuticals plc
        • Table Jazz Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Johnson & Johnson
        • Table Johnson & Johnson Pharmaceutical's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table Alza's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table Janssen's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • KV Pharmaceutical Company
        • Table KV Pharmaceutical's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Merck & Company
        • Table Merck & Co.'s Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Novartis
        • Table Novartis' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table Alcon's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Novo Nordisk
        • Table Novo Nordisk's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • NPS Pharmaceuticals
        • Table NPS Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Octapharma USA, Inc.
        • Table Octapharma's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Onyx Pharmaceuticals, Inc.
        • Table Onyx Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Otsuka Pharmaceutical Co., Inc.
        • Table Otsuka Pharmaceutical's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Pacira Pharmaceuticals, Inc.
        • Table Pacira Pharmaceutical's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Pfizer, Inc.
        • Table Pfizer's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Rare Disease Therapeutics, Inc.
        • Table Rare Disease Therapeutics' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Reckitt Benckiser Group plc
        • Table Reckitt Benckiser's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Regeneron Pharmaceuticals, Inc.
        • Table Regeneron Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Roche
        • Table Roche's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table Genentech's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Salix Pharmaceuticals, Inc.
        • Table Salix Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Sanofi
        • Table Sanofi's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table Genzyme's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Savient Pharmaceuticals, Inc.
        • Table Savient Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Seattle Genetics, Inc.
        • Table Seattle Genetics' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Shire Plc
        • Table Shire's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Sigma-Tau Pharmaceuticals, Inc.
        • Table Sigma Tau's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Spectrum Pharmaceuticals
        • Table Spectrum Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Takeda Pharmaceutical Company Ltd.
        • Table Millennium Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Talon Therapeutics, Inc.
        • Table Talon Therapeutics' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Teva Pharmaceuticals
        • Table Teva's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
        • Table Cephalon's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • United Therapeutics Corporation
        • Table United Therapeutics' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Valeant Pharmaceuticals International, Inc.
        • Table Valeant Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • Vertex Pharmaceuticals, Inc.
        • Table Vertex Pharmaceuticals' Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
      • ViroPharma, Inc.
        • Table ViroPharma's Orphan Drug Approvals Granted by FDA (1983 - May 1, 2013)
  • E.U. Orphan Drugs
    • OVERVIEW
      • Table Orphan Drug Designations and Approvals Granted by the EMA 2000-2013*
    • RECENT ORPHAN DRUG DESIGNATIONS
      • Table Orphan Drug Designations Granted by EMA (January 1, 2012 - December 31, 2012)
      • Table Orphan Drug Designations Granted by EMA (2013, January - April)
    • SELECT COMPANY ORPHAN DRUG ACTIVITIES
      • Actelion Pharmaceuticals
      • Adienne Pharma & Biotech
      • Alexion Pharmaceuticals
      • Amgen
      • Bayer AG
      • BioMarin Pharmaceutical, Inc.
      • Bristol-Myers Squibb
      • Celgene Corporation
      • Eisai Co., Ltd.
      • Gilead Sciences, Inc.
      • GlaxoSmithKline
      • Novartis
      • Orphan Europe S.A.R.L.
      • Pfizer, Inc.
      • Sanofi
      • Shire Plc
      • Vertex Pharmaceuticals, Inc.
  • Japan Orphan Drugs
    • OVERVIEW
      • Table Orphan Drug Designations and Approvals Granted by the MHLW 1993-2012*
    • RECENT ORPHAN DRUG DESIGNATIONS
      • Table Orphan Drug Designations Granted by MHLW (January 1, 2012 - November 14, 2012)
    • SELECT COMPANY ORPHAN DRUG ACTIVITIES
      • Actelion Pharmaceuticals
      • Alexion Pharmaceuticals
      • Bristol-Myers Squibb
      • Celgene Corporation
      • GlaxoSmithKline
      • Johnson & Johnson
      • Merck Serono
      • Mitsubishi Tanabe
      • Novartis
      • Pfizer, Inc.
      • Roche
      • Sanofi
  • Competitor Trends and Practices
    • ACQUISITIONS AND AGREEMENTS
    • U.S. COMPETITOR MARKET ANALYSIS
      • Amgen
      • Roche
      • Celgene
      • Novartis
      • Abbott
      • Biogen Idec
      • Bayer
      • Eli Lilly
      • Bristol-Myers Squibb
      • Novo Nordisk
      • Sanofi
      • Allergan
      • Other Companies
        • Table Competitor Analysis, U.S. Orphan Drug Market, 2012
  • Orphan Drug Trends
    • INTRODUCTION
    • U.S. REGULATION SHAPING THE ORPHAN DRUG SEGMENT
      • Orphan Drug Act of 1983
      • Rare Disease Act of 2002
    • OFFICE OF ORPHAN PRODUCTS DEVELOPMENT
    • HUMANITARIAN USE DEVICE PROGRAM
    • POSITIVES AND NEGATIVES OF THE ORPHAN DRUG DESIGNATION
      • Orphan Drug Designation in the U.S.
      • Orphan Drug Designation in the E.U.
      • Orphan Drug Designation in Japan
      • Orphan Drug Designation in Canada
      • Orphan Drug Designation in Australia
    • FACTORS AFFECTING THE HEALTH INDUSTRY
      • Aging of the Population
    • POPULATION STATISTICS
      • Global Population Trends
        • Table The Global Population, 1980-2050
        • Table Global Population Trends Age 65+, 2000-2050
      • U.S. Population Trends
        • Table The U.S. Population, 1980-2050
        • Table Percent U.S. Population Over Age 65 by Year, 2000-2050
      • Global Trends in Life Expectancy
        • Table Average Life Expectancy in Years by Country 1980 and 2012
      • Global Trends in Birth Rates
        • Table Crude Birth Rate per 1,000 Persons 2000, 2005, 2010, Estimated 2012 and Projected 2020
    • GLOBAL HEALTHCARE SPENDING TRENDS
      • Table Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2010
      • General Economic Trends by Country
        • Table Average Annual Growth of GDP by Country 2007-2011
    • U.S. HEALTH INDUSTRY TRENDS
      • Table National Healthcare Expenditures in the United States 1960-2020 (millions)
      • U.S. Healthcare Challenges
      • Economic Trends in the U.S.
      • U.S. Health Expenditures by Type
        • Table National Health Expenditure Amounts, by Type of Expenditure: Calendar Years 2015-2021 1 (In billions of dollars)
  • U.S. Orphan Drug Market Size and Opportunity
    • OVERVIEW
    • MARKET SIZE AND FORECAST
      • Table The U.S. Orphan Drug Market 2007-2017 (in millions of dollars)
    • MARKETS BY PRODUCT CLASSIFICATION
      • Oncology
        • Table The U.S. Market for Orphan Drugs with Oncology Targets 2007-2017 (in millions of dollars)
      • Hematology
        • Table The U.S. Market for Orphan Drugs with Hematology Targets 2007-2017 (in millions of dollars)
      • Musculoskeletal
        • Table The U.S. Market for Orphan Drugs with Musculoskeletal Targets 2007-2017 (in millions of dollars)
      • Neurology
        • Table The U.S. Market for Orphan Drugs with Neurology Targets 2007-2017 (in millions of dollars)
      • Endocrinology
        • Table The U.S. Market for Orphan Drugs with Endocrinology Targets 2007-2017 (in millions of dollars)
      • Metabolic
        • Table The U.S. Market for Orphan Drugs with Metabolic Targets 2007-2017 (in millions of dollars)
      • Others
        • Table The U.S. Market for Orphan Drugs with Other Disease Targets 2007-2017 (in millions of dollars)
  • World Market Summary-Orphan Drugs
    • OVERVIEW
      • Table World Orphan Drug Market 2007-2017 (in millions of dollars)
    • MARKET DISTRIBUTION: UNITED STATES AND WORLD MARKETS
      • Table World Orphan Drug Market: Distribution by United States and Rest of World, 2007-2017
  • Corporate Profiles
    • INTRODUCTION
    • ORPHAN DRUG DESIGNATIONS BY COMPANY:AU.S.ANALYSIS
    • COMPANY PROFILES
      • ABBOTT LABORATORIES
      • Company Overview
      • Performance Review
    • ABBVIE
      • Company Overview
      • Performance Review
    • ACTELION
      • Company Overview
      • Performance Review
    • ASTELLAS
      • Company Overview
      • Performance Review
    • ASTRAZENECA
      • Company Overview
      • Performance Review
    • BAXTER
      • Company Overview
      • Performance Review
    • BAYER
      • Company Overview
      • Performance Review
    • BIO PRODUCTS LABORATORY
      • Company Overview
    • BIOGEN IDEC
      • Company Overview
      • Performance Review
    • BIOMARIN
      • Company Overview
      • Performance Review
    • BOEHRINGER INGELHEIM
      • Company Overview
      • Performance Review
    • BRISTOL-MYERS SQUIBB
      • Company Overview
      • Performance Review
    • CANGENE
      • Company Overview
      • Performance Review
    • CELGENE
      • Company Overview
      • Performance Review
    • CSLBEHRING
      • Company Overview
      • Performance Review
    • DEPOMED
      • Company Overview
      • Performance Review
    • EISAI
      • Company Overview
      • Performance Review
    • ELI LILLY
      • Company Overview
      • Performance Review
    • EMD SERONO
      • Company Overview
      • Performance Review
    • EXELIXIS
      • Company Overview
      • Performance Review
    • GILEAD SCIENCES
      • Company Overview
      • Performance Review
    • GLAXOSMITHKLINE
      • Company Overview
      • Performance Review
    • IMMUNOGEN
      • Company Overview
      • Performance Review
    • INSMED
      • Company Overview
      • Performance Review
    • JOHNSON &JOHNSON
      • Company Overview
      • Performance Review
    • LUITPOLD
      • Company Overview
      • Performance Review
    • MERCK&CO
      • Company Overview
      • Performance Review
    • MILLENNIUM PHARMACEUTICALS
      • Company Overview
      • Performance Review
    • NBI PHARMACEUTICALS
      • Company Overview
    • NOVARTIS
      • Company Overview
      • Performance Review
    • NOVO NORDISK
      • Company Overview
      • Performance Review
    • NPS PHARMACEUTICALS
      • Company Overview
      • Performance Review
    • PFIZER
      • Company Overview
      • Performance Review
    • ROCHE
      • Company Overview
      • Performance Review
    • SANOFI
      • Company Overview
      • Performance Review
    • SEATTLE GENETICS
      • Company Overview
      • Performance Review
    • SHIRE
      • Company Overview
      • Performance Review
    • SIGMA TAU
      • Company Overview
      • Performance Review
    • SOLIGENIX
      • Company Overview
      • Performance Review
    • SPECTRUM
      • Company Overview
      • Performance Review
    • SWEDISH ORPHAN BIOVITRUM
      • Company Overview
      • Performance Review
    • TEVA
      • Company Overview
      • Performance Review
    • UNITED THERAPEUTICS
      • Company Overview
      • Performance Review
    • VALEANT
      • Company Overview
      • Performance Review
    • XENOPORT
      • Company Overview
      • Performance Review
  • Regulatory Authorities and Organizations
  • List of Companies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report